Literature DB >> 21969099

Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?

Peter Wood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21969099      PMCID： PMC7100643          DOI： 10.1007/s00210-011-0694-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  15 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

2.  Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.

Authors:  G Tougas; W J Snape; M H Otten; D L Earnest; K-E Langaker; R E Pruitt; E Pecher; B Nault; M A Rojavin
Journal:  Aliment Pharmacol Ther       Date:  2002-10       Impact factor: 8.171

3.  New horizons in vascular biology and thrombosis: Highlights from EMVBM 2009.

Authors:  Sebastian F Mause; Christian Weber; José Sampol; Francoise Dignat-George
Journal:  Thromb Haemost       Date:  2010-08-05       Impact factor: 5.249

4.  The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention.

Authors:  Matthew J Price
Journal:  Circ Cardiovasc Interv       Date:  2010-06-01       Impact factor: 6.546

Review 5.  Review article: the safety profile of tegaserod.

Authors:  P Schoenfeld
Journal:  Aliment Pharmacol Ther       Date:  2004-11       Impact factor: 8.171

Review 6.  Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.

Authors:  Ron Schey; Satish S C Rao
Journal:  Dig Dis Sci       Date:  2011-04-27       Impact factor: 3.199

7.  Assessment of platelet activation in myeloproliferative disorders with complementary techniques.

Authors:  Emilse Bermejo; Maria F Alberto; Susana S Meschengieser; Maria A Lazzari
Journal:  Blood Coagul Fibrinolysis       Date:  2004-04       Impact factor: 1.276

8.  Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.

Authors:  Victor L Serebruany; Mohamed El Mouelhi; Hans-Jürgen Pfannkuche; Kristine Rose; Martin Marro; Dominick J Angiolillo
Journal:  Am J Ther       Date:  2010 Nov-Dec       Impact factor: 2.688

9.  A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.

Authors:  J Novick; P Miner; R Krause; K Glebas; H Bliesath; G Ligozio; P Rüegg; M Lefkowitz
Journal:  Aliment Pharmacol Ther       Date:  2002-11       Impact factor: 8.171

10.  5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine.

Authors:  J R Grider; A E Foxx-Orenstein; J G Jin
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682
View more
  3 in total

Review 1.  Novel pharmacological therapies for management of chronic constipation.

Authors:  Marina A Gonzalez-Martinez; Nayeli X Ortiz-Olvera; Jorge Mendez-Navarro
Journal:  J Clin Gastroenterol       Date:  2014-01       Impact factor: 3.062

Review 2.  Recent Updates on the Treatment of Constipation.

Authors:  Han Seung Ryu; Suck Chei Choi
Journal:  Intest Res       Date:  2015-10-15

3.  Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.

Authors:  Max J Schmulson; Jazmin Chiu-Ugalde; Adolfo Sáez-Ríos; Aurelio López-Colombo; Gualberto J Mateos-Pérez; José María Remes-Troche; Sergio Sobrino-Cossio; Julio C Soto-Pérez; José L Tamayo de la Cuesta; Oscar T Teramoto-Matsubara; Juan C López-Alvarenga
Journal:  J Clin Gastroenterol       Date:  2020-04       Impact factor: 3.174
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.